It is locally used together with photo-dynamic therapy (especial blue light) as a treatment of Actinic Dermatitis and Basocelular Carcinoma.
At latest update, relevant information on excretion into breast milk was not found.
Absorption through the skin is very low (0.26 % of administered dose), hence, a low or non-significant level in the mother's plasma should be expected.
In case that a complete elimination of drug would be desired, a time period equivalent to ten times a half-life (Mean time) should be observed after drug administration to resume breastfeeding.
In this case it would be equal to 8-10 hours.
In the mean while, pump-and-dump regularly to maintain milk production.
Do not apply it on the breast or cleanse it thoroughly to keep the baby from swallowing.
We do not have alternatives for 5-Aminolevulinic Acid.
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
- Methyl Aminolaevulinate Hydrochloride
Drug trade names
- EMEA. Ácido 5-aminolevulínico. Ficha técnica 2011 Full text (in our servers)
- Sandberg C, Halldin CB, Ericson MB, Larkö O, Krogstad AL, Wennberg AM. Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo. Br J Dermatol. 2008Abstract
- McLoone N, Donnelly RF, Walsh M, Dolan OM, McLoone S, McKenna K, McCarron PA. Aminolaevulinic acid diffusion characteristics in 'in vitro' normal human skin and actinic keratosis: implications for topical photodynamic therapy. Photodermatol Photoimmunol Photomed. 2008Abstract
- New Zealand Datasheet. Methyl aminolevulinate. Drug Summary. 2008 Full text (in our servers)
- SNS. Aminolevulinato de metilo (ALM). Información Terapéutica. 2005 Full text (in our servers)